Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 12/20 | 0.49 |
| ▸ | MMP3 | P08254 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9596147 | 0.78 | POLB (0.65) | CYP2C19POLBCYP3A4MMP8MMP3 | |
| SCHEMBL18711805 | 0.78 | POLB (0.65) | CYP2C19POLBCYP3A4GLA | |
| SCHEMBL12871199 | 0.77 | POLB (0.55) | CYP2C19POLBCYP3A4GLAMMP8 | |
| SCHEMBL7270109 | 0.76 | CYP2C19 (0.54) | CYP2C19POLBCYP3A4GLAMMP8 | |
| SCHEMBL18711811 | 0.75 | POLB (0.61) | CYP2C19POLBCYP3A4 | |
| SCHEMBL14183936 | 0.75 | HDAC8 (0.62) | CYP2C19POLBCYP3A4 | |
| SCHEMBL8538945 | 0.74 | CYP2C19 (0.52) | CYP2C19POLBCYP3A4GLAMMP8 | |
| SCHEMBL7270808 | 0.73 | CYP2C19 (0.50) | CYP2C19POLBCYP3A4GLAMMP8 | |
| SCHEMBL7279514 | 0.72 | CYP2C19 (0.47) | CYP2C19POLBCYP3A4GLAMMP8 | |
| SCHEMBL10284071 | 0.71 | SMN1; SMN2 (0.70) | POLBGLAMMP8MMP3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | CYP2C19 4487/4885POLB 4760/4885CYP3A4 4321/4885 |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | CYP2C19 4487/4885POLB 4760/4885CYP3A4 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.